Intervention not reported
Emergence of non albicans species of Candida ‐ At 24 months Fungal Smears · prevention and treatment of vulvovaginal candidiasis in women with HIV infection
The intervention showed no clear difference in emergence of non albicans species of Candida ‐ At 24 months Fungal… (moderate certainty).
1 finding from 1 review
Intervention not reported
In Vitro resistance to azoles ‐ Candida albicans MIC >= 64 micrograms/ml · prevention and treatment of vulvovaginal candidiasis in women with HIV infection
The intervention showed no clear difference in in Vitro resistance to azoles ‐ Candida albicans MIC >= 64… (moderate certainty).
1 finding from 1 review
Intervention not reported
In Vitro resistance to azoles ‐ Non albicans Candida MIC>= 64 micrograms/ml · prevention and treatment of vulvovaginal candidiasis in women with HIV infection
The intervention probably leads to higher in Vitro resistance to azoles ‐ Non albicans Candida MIC>= 64… (moderate certainty).
1 finding from 1 review
Cure · prevention and treatment of vulvovaginal candidiasis in women with HIV infection
Lactobacillus led to lower cure compared with clotrimazole; GRADE not reported.
1 finding from 1 review
Episodes of confirmed vaginal candidiasis fungal smear · prevention and treatment of vulvovaginal candidiasis in women with HIV infection
Lactobacillus showed no clear difference in episodes of confirmed vaginal candidiasis fungal smear compared with clotrimazole (low certainty).
1 finding from 1 review
Intervention not reported
Mortality ‐ not measured · patients with first‐line ART failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Disease progression ‐ not measured · patients with first‐line ART failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Severe adverse events · patients with first‐line ART failure
1 finding from 1 review
Intervention not reported
Adherence/tolerability/retention ‐ not reported · patients with first‐line ART failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Proportion achieving VL <50 copies/ml · patients with first‐line ART failure
The intervention showed no clear difference in proportion achieving VL <50 copies/ml (low certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in CD4 · patients with first‐line ART failure
1 finding from 1 review
Death · patients with asymptomatic, HIV‐infected, treatment naive adults
Early ART probably leads to lower death compared with standard or deferred ART (CD4 <= 200 or CD4 <= 250 cells/µl) (moderate certainty).
1 finding from 1 review
Tuberculosis · patients with asymptomatic, HIV‐infected, treatment naive adults
Early ART showed no clear difference in tuberculosis compared with standard or deferred ART (CD4 <= 200 or CD4 <= 250 cells/µl) (moderate certainty).
1 finding from 1 review
Disease progression measured by opportunistic disease Opportunistic disease events · patients with asymptomatic, HIV‐infected, treatment naive adults
Early ART showed no clear difference in disease progression measured by opportunistic disease Opportunistic… compared with standard or deferred ART (CD4 <= 200 or CD4 <= 250 cells/µl) (low certainty).
1 finding from 1 review
Infant HIV Transmission or Death at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant HIV Transmission or Death at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at Birth · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at Birth compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at 6 Weeks · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at 6 Weeks compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r may leads to lower mother to Child Transmission at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at 12 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora continued: AZT/3TC/LPV‐r changes mother to Child Transmission at 12 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Maternal Resistance · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether lehman: AZT/3TC/NVP changes maternal Resistance compared with short Course AZT/sdNVP (very low certainty).
1 finding from 1 review